Metal detector, cornerstone in quality management
Chronicle Pharmabiz
|September 18, 2025
IDENTIFYING the source of contamination and maintaining quality norms and standards of hygiene can help manufacture safe and quality products stipulated to government norms.
Metal detector is a key cornerstone in quality control (QC) management for pharmaceutical processing sector. Metal detection forms a key part of product quality assurance (QA) in pharmaceuticals and helping to prove the quality of manufacturing process and compliance with regulations.
Currently available metal detectors utilize latest digital signal processing technology to detect and reject ferrous and nonferrous metals. Latest pharmaceutical detectors have advantages such as highest processing power, superior speed, accuracy with additional features like current good manufacturing practices, design and construction suited for the US health regulatory compliance and meet the demanding quality standards required by the industry.
Advancing quality inspection system
Pharmaceutical products safety norms and legislation continue to come under highly increasing scrutiny. Thorough risk assessments are enabled by the separation and speciation of elements in a drug product, allowing for more detailed evaluations of both the benefits and risks presented by elements within a particular sample.
More and more studies demonstrate that free elements and various bound states differ greatly in toxicity, the speciation of elements will become even more critical almost any stage of drug development and manufacturing, impurities, contaminants, and residuals can be introduced into pharmaceuticals and biopharmaceuticals.
The presence of elemental impurities in raw materials, APIs, drug product, and packaging materials can cause significant disruption to even the most robust path-to-market, as drug products will not comply with necessary regulations to ensuring product safety and efficacy.
This story is from the September 18, 2025 edition of Chronicle Pharmabiz.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Chronicle Pharmabiz
Chronicle Pharmabiz
US FDA fortifies alliance with Telangana DCA
A high-level delegation from the US FDA concluded a significant meeting with the DCA in Telangana, two days ago, at the DCA office in Hyderabad.
2 mins
December 11, 2025
Chronicle Pharmabiz
India exploring possibilities to expand WHO standards for Indian medicines
INDIA is looking at possibilities to expand the World Health Organisation (WHO) global benchmarking standards for medicines, in order to unify and strengthen the drug regulatory mechanism for safety, quality and efficacy of medicines sold in the country.
1 min
December 11, 2025
Chronicle Pharmabiz
Eli Lilly gets US FDA approval for Jaypirca
Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor.
1 mins
December 11, 2025
Chronicle Pharmabiz
Haryana DCA focuses on quality overhaul
THE Haryana drug control administration (DCA) is undertaking a major organizational overhaul focused on quality system upgrades and regulatory capacity building, particularly in response to the revised Schedule M norms.
2 mins
December 11, 2025
Chronicle Pharmabiz
DoC seeks inputs on trade issues faced with Japan
THE Department of Commerce (DoC), under the Union Commerce Ministry, has sought inputs from the industry on specific issues being faced in pharma trade with Japan.
1 min
December 11, 2025
Chronicle Pharmabiz
AIOCD asks traders to strictly comply with ban on 35 FDCs
THE All India Organisation of Chemists and Druggists (AIOCD) has issued an urgent internal circular to all its state and Union territory trade bodies, demanding immediate and strict compliance with the ban on 35 fixed dose combinations (FDCs).
3 mins
December 11, 2025
Chronicle Pharmabiz
US FDA approves Bristol Myers Squibb's Breyanzi
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has granted approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.
2 mins
December 11, 2025
Chronicle Pharmabiz
CN Water presents AQU@Sense MB
CN Water is now combining core water-system expertise with digital assurance has launched AQU@Sense which delivers microbial test results in under 30 minutes, replacing traditional 5 to 7 days culture based methods.
1 min
December 11, 2025
Chronicle Pharmabiz
Pharma logistics sees policy push as key catalyst for growth
INDIAN pharma's logistics sector is getting major boost from emerging policy support.
2 mins
December 11, 2025
Chronicle Pharmabiz
Lack of financial aid, expertise mar MSME prospects to meet revised Sch M deadline
INDUSTRY experts have raised alarm that lack of financial assistance and guidance on technical expertise have marred pharma MSMEs’ prospects to comply with revised Schedule M guidelines of December 31, 2025.
2 mins
December 11, 2025
Listen
Translate
Change font size

